维得利珠单抗与乌司奴单抗相比抗TNF药物在妊娠期炎症性肠病女性中的安全性
基于法国EPI-MERES登记数据,纳入2014至2021年妊娠期炎症性肠病女性,比较维得利珠单抗、乌司奴单抗与抗TNF药物的妊娠结局及子代并发症。经倾向性评分匹配后,维得利珠单抗和乌司奴单抗均未增加流产、剖宫产、死产、早产、严重感染、恶性肿瘤或先天畸形的风险;乌司奴单抗暴露者小于胎龄儿风险升高。总体安全性令人放心,需进一步研究确认。
要点
- 维得利珠单抗与抗TNF相比未增加不良妊娠结局及子代并发症风险
- 乌司奴单抗与抗TNF相比未增加多数不良结局风险,但小于胎龄儿风险升高
- 结论总体令人放心,原文指出需进一步研究确认这些发现
核心结论
- 与抗TNF相比,妊娠期使用维得利珠单抗或乌司奴单抗总体安全性令人放心。
- 乌司奴单抗暴露与小于胎龄儿风险升高相关。
- 原文指出需进一步研究确认这些发现。
研究设计与样本
- 基于法国EPI-MERES登记库的全国性综合数据,识别2014至2021年妊娠期炎症性肠病女性。
- 按妊娠期治疗暴露比较妊娠结局及子代并发症,并对母亲、炎症性肠病及妊娠特征进行倾向性评分匹配。
- 398例维得利珠单抗暴露妊娠与1592例抗TNF暴露妊娠比较;464例乌司奴单抗暴露妊娠与1856例抗TNF暴露妊娠比较。
主要发现
- 与抗TNF相比,维得利珠单抗和乌司奴单抗均未增加流产、剖宫产、死产、早产、严重感染、恶性肿瘤或子代先天畸形风险。
- 乌司奴单抗暴露者小于胎龄儿出生风险升高。
关键数值与推荐
- 维得利珠单抗暴露妊娠398例,对照抗TNF暴露妊娠1592例。
- 乌司奴单抗暴露妊娠464例,对照抗TNF暴露妊娠1856例。
- 乌司奴单抗暴露者小于胎龄儿风险升高,其余结局与抗TNF相比未见风险增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出需进一步研究确认这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Limited data are available on the consequences of prenatal exposure to vedolizumab and ustekinumab. We aimed to compare the safety of vedolizumab and ustekinumab with that of anti-tumor necrosis factor (TNF) in pregnant women with inflammatory bowel diseases (IBD). METHODS: Using nationwide, comprehensive data of the EPI-MERES registry, we identified pregnancies in women with IBD in France, exposed to anti-TNF, vedolizumab, and ustekinumab between 2014 and 2021. We compared pregnancy outcomes and complications in the offspring according to treatment exposure during pregnancy. We applied a propensity score matching for maternal, IBD, and pregnancy characteristics. RESULTS: Three hundred ninety-eight pregnancies exposed to vedolizumab were compared with 1592 pregnancies exposed to anti-TNF; 464 pregnancies exposed to ustekinumab were compared with 1856 pregnancies exposed to anti-TNF. Overall, compared with anti-TNF, neither vedolizumab nor ustekinumab was associated with increased risks of abortion, caesarean section, stillbirth, preterm birth, serious infections, malignancies, or congenital abnormality in children. Women exposed to ustekinumab had an increased risk of small for gestational age births. CONCLUSIONS: Overall, the safety of vedolizumab and ustekinumab compared with anti-TNF use during pregnancy is reassuring. Further studies are needed to confirm these findings.
引用
- Meyer A, Miranda S, Drouin J, et al. Safety of Vedolizumab and Ustekinumab Compared With Anti-TNF in Pregnant Women With Inflammatory Bowel Disease. Clin Gastroenterol Hepatol. 2024. PMID: 38199301. doi:10.1016/j.cgh.2023.12.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。